Overview:
As novel therapies and new combination approaches lead to improved outcomes for patients with multiple myeloma (MM), it is more critical than ever to develop personalized treatment plans that account for individual patient- and disease-related risk factors. Moving these novel therapies into earlier settings also brings the challenge of determining how they should be sequenced. Similar issues have arisen in heavily pretreated MM now that there are several approved T-cell redirection therapies with different mechanisms and targets.
This live educational symposium will bring together leading experts to discuss the latest advances in the treatment of MM, from newly diagnosed to relapsed/refractory disease, with key topics including when to consider upfront quadruplet therapy, optimal ways to sequence treatments after the first or second relapse, and how to incorporate CAR T-cell therapies and bispecific antibodies into everyday practice.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Analyze key safety and efficacy data from pivotal clinical trials assessing both current and emerging therapies designed for patients with MM
- Determine the impact of disease- and patient-specific factors, along with prior treatment history, on therapy selection for patients with MM
- Formulate proactive approaches to monitor, prevent, and mitigate treatment-related toxicities in both frontline and relapsed/refractory MM settings
Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology and Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA
Suzanne Lentzsch, MD, PhD
Professor of Clinical Medicine, Columbia University
Director, Multiple Myeloma and Amyloidosis Service
Columbia University Irving Medical Center
New York, NY
Amrita Krishnan, MD
Director of Judy and Bernard Briskin Multiple Myeloma Center
Professor of Hematology/Hematopoietic Cell Transplantation
City of Hope Cancer Center
Duarte, CA
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity will be certified for 1.0 AMA PRA Category 1 Credit™ with 1.0 ABIM MOC Knowledge points for physicians, 1.0 NCPD contact hour for nurses and 1.0 contact hour (0.1 CEU) for pharmacists.